Form 4: PTC Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4
Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units (RSUs).
Summary
- On January 7th and 8th, 2025, Neil Gregory Almstead, the Chief Technical Operations Officer of PTC Therapeutics, sold shares of the company's common stock.
- The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- On January 7th, 1,265 shares were sold at a price of $45.34, and another 55 shares were sold at the same price.
- On January 8th, 1,552 shares were sold at $44.50, and an additional 107 shares were sold at $44.50.
- Following these transactions, Almstead directly owns 103,231 shares and indirectly owns 5,975 shares through his spouse.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (stock sale for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's performance.
Industry Context
Executive stock sales are a common occurrence, particularly when RSUs vest, as executives often sell a portion of the shares to cover the associated tax liabilities. This is a normal part of executive compensation and wealth management.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations upon RSU vesting are standard practice across the pharmaceutical and biotechnology industries.
- Companies like Amgen, Biogen, and Gilead Sciences also see similar transactions by their executives regularly.
- The amounts sold by Almstead are relatively small compared to the total shares he owns, which is typical for these types of transactions.
Stakeholder Impact
- The stock sales are unlikely to have a significant impact on shareholders, as they are related to tax obligations and represent a small portion of the executive's holdings.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 01/06/2021 | Date of grant of 600 RSUs. |
| 01/07/2022 | Date of grant of 780 RSUs. |
| 01/05/2023 | Date of grant of 710 and 17,000 RSUs. |
| 01/07/2025 | Sale of 1,265 and 55 shares of common stock. |
| 01/08/2025 | Sale of 1,552 and 107 shares of common stock. |
| 01/10/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.